In a population of adult patients previously treated with Humira® who are targeted to get switched to a biosimilar (FK adalimumab) and followed up for a period of 12 months under routine medical practice conditions.~Primary objective: to define predictive factors for the persistence of treatment~Secondary objectives:~To assess the therapeutic benefit and the tolerability of the treatment~To describe the reasons for treatment discontinuations occurring during follow-up
A prospective, longitudinal, multicentre, observational cohort follow-up study conducted in France.